Abstract |
D-dimer (DD)--an end product of fibrinolysis--was measured in serum by enzyme immunoassay using a monoclonal antibody to the gamma gamma crosslink in patients with ovarian cancer, before primary surgery and during chemotherapy for 12 months or more. Serial DD levels were found to have a high sensitivity for the detection of tumor in patients with subclinical disease (91%) as well as for predicting progression of disease (100%). As determined by a careful second-look laparotomy in patients with complete clinical remission the DD marker was highly predictive of tumors less than 1 cm. The negative predictive value (82%) was higher than the positive predictive value (69%). However, there were 31% of the patients who showed a false-positive result; a close examination of the clinical data of these 9 patients failed to reveal an explanation for the positive DD levels. Despite the lack of specificity (50% in the present series), the findings support the use of DD in the assessment of patients with ovarian cancer, especially those with subclinical disease.
|
Authors | S K Khoo, D B Rylatt, P Parsons, K Wilson, M J Webb, G Dickie, J Kearsley, E V Mackay |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 29
Issue 2
Pg. 188-98
(Feb 1988)
ISSN: 0090-8258 [Print] United States |
PMID | 3338671
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Fibrin Fibrinogen Degradation Products
- fibrin fragment D
|
Topics |
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- False Negative Reactions
- False Positive Reactions
- Female
- Fibrin Fibrinogen Degradation Products
(metabolism)
- Humans
- Laparotomy
- Ovarian Neoplasms
(blood, drug therapy, surgery)
- Predictive Value of Tests
- Prognosis
- Radioimmunoassay
|